ImmusanT CEO Leslie Williams to Discuss Immunology of Celiac Disease at 2018 BIO International Convention
May 24 2018 - 8:00AM
Business Wire
-- ImmusanT will also provide a corporate
update --
ImmusanT, Inc., a clinical stage company that is leveraging its
Epitope-Specific Immuno-Therapy (ESIT) platform to translate and
deliver first-in-class peptide-based immune therapies to patients
living with autoimmune diseases, today announced that Chief
Executive Officer, Leslie Williams will participate on a panel and
provide a company presentation at the 2018 BIO International
Convention, occurring June 4-7, 2018 in Boston, MA.
Ms. Williams and a panel of experts will discuss approaches and
advancements made in the non-oncology immunotherapy space. In
addition, Ms. Williams will provide a corporate update presentation
as the company prepares to enter Phase 2 trials for lead candidate,
Nexvax2®, a vaccine in development for the treatment of celiac
disease.
Details of the panel and presentation are as follows:
Panel Title: Immuno_________ (Fill in the Blank) –
Translating Immunological Insights from Oncology to Other Disease
AreasDate: Tuesday, Jun 5, 2018Time: 1:45 PM–2:45 PM
ETLocation: Room 210B, Level 2Track: Next Generation
Biotherapeutics
Presentation Date: Wednesday, June 6, 2018Time:
2:30 PM–2:45 PM ETLocation: Company Presentation Theatre 3,
Level 0
About Nexvax2®Nexvax2® is the most advanced
therapeutic approach for celiac disease in clinical development
today that targets the fundamental cause of the disease; the loss
of immune tolerance to gluten. Nexvax2 is a therapeutic vaccine
that reprograms the T-cells responsible for the symptoms of celiac
disease to stop triggering a pro-inflammatory response. Nexvax2
intends to protect patients with celiac disease against inadvertent
exposure to gluten.
About ImmusanT, Inc.ImmusanT is a privately held
biotechnology company focused on protecting patients with celiac
disease against the effects of gluten. By harnessing new
discoveries in immunology, ImmusanT aims to improve diagnosis and
medical management of celiac disease by protecting against the
effects of gluten exposure while patients maintain a gluten-free
diet. The company is developing Nexvax2®, a therapeutic vaccine for
celiac disease, and diagnostic and monitoring tools to improve
celiac disease management. ImmusanT’s targeted immunotherapy
discovery platform can be applied to a variety of autoimmune
diseases. To learn more about ImmusanT, visit www.ImmusanT.com, or
follow ImmusanT on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180524005224/en/
MacDougall Biomedical CommunicationsGeorge E. MacDougall,
781-235-3093george@macbiocom.com